A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin 2 vaccine poliovirus

Journal of Virology

Volumn 90, Issue 13, 2016, Pages 5978-5988

  Korotkova, Ekaterina A ^a,b   Gmyl, Anatoly P ^b   Yakovenko, Maria L ^a,b   Ivanova, Olga E ^b   Eremeeva, Tatyana P ^b   Kozlovskaya, Liubov I ^b   Shakaryan, Armen K ^b   Lipskaya, Galina Y ^a   Parshina, Irina L ^c   Loginovskikh, Nataliya V ^d   Morozova, Nadezhda S ^e   Agol, Vadim I ^a,b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c State Center for Sanitary and Epidemiological Inspection in Altai Region   (Russian Federation)

^d Center for Hygiene and Epidemiology in the Omsk Region   (Russian Federation)

^e Federal Service for Surveillance on Consumer Rights Protection and Human Well Being   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; PROTEIN VP1; PROTEIN VP2; VIRAL PROTEIN; VIRUS ANTIBODY;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CHICKENPOX; CHILD; EPIDEMIC; FECES ANALYSIS; FEMALE; HUMAN; HUMAN POLIOVIRUS 2; INFANT; MALE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; OTITIS; PARALYSIS; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RUSSIAN (PEOPLE); VIRUS GENOME; BLOOD; ENTEROVIRUS C; GENETIC RECOMBINATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR EVOLUTION; MUTATION; PARAPLEGIA; PATHOGENICITY; POLIOMYELITIS VIRUS; RUSSIAN FEDERATION; TRANSMISSION; VIROLOGY;

ANTIBODIES, VIRAL; DISEASE OUTBREAKS; ENTEROVIRUS C, HUMAN; EVOLUTION, MOLECULAR; GENOME, VIRAL; HUMANS; MUTATION; PARAPLEGIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RECOMBINATION, GENETIC; RUSSIA; VIRAL PROTEINS;

EID: 84975284882     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00277-16     Document Type: Article

References (56)

1. Platt LR, Estívariz CF, Sutter RW. 2014. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 210:S380-S389. http://dx.doi.org/10.1093/infdis/jiu184.
2. Burns CC, Diop OM, Sutter RW, Kew OM. 2014. Vaccine-derived polioviruses. J Infect Dis 210:S283-S293. http://dx.doi.org/10.1093/infdis/jiu295.
3. World Health Organization. 2015. Reporting and classification of vaccine-derived polioviruses. GPEI guidelines. World Health Organization, Geneva, Switzerland. http://www.polioeradication.org/Portals/0/Document/Resources/VDPV_ReportingClassification.pdf.
4. Sabin AB, Boulger LR. 1973. History of Sabin attenuated oral live vaccines. J Biol Stand 1:115-118. http://dx.doi.org/10.1016/0092-1157(73)90048-6.
5. Agol VI. 2006. Vaccine-derived polioviruses. Biologicals 34:103-108. http://dx.doi.org/10.1016/j.biologicals.2006.02.007.
6. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59:587-635. http://dx.doi.org/10.1146/annurev.micro.58.030603.123625.
7. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI. 2002. Long-term circulation of vaccinederived poliovirus that causes paralytic disease. J Virol 76:6791-6799. http://dx.doi.org/10.1128/JVI.76.13.6791-6799.2002.
8. Yakovenko ML, Korotkova EA, Ivanova OE, Eremeeva TP, Samoilovich E, Uhova I, Gavrilin GV, Agol VI. 2009. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J Virol 83:3402-3406. http://dx.doi.org/10.1128/JVI.02122-08.
9. Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, Cebelinski EA, Chen Q, Jorba J, Kew OM, Pallansch MA, Oberste MS, Schleiss M, Davis JP, Warshawsky B, Squires S, Hull HF, Vaccine-Derived Poliovirus Investigations Group. 2009. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 199:391-397. http://dx.doi.org/10.1086/596052.
10. Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, Ali Pate M, Abanida EA, Gasasira A, Iber J, Chen Q, Vincent A, Chenoweth P, Henderson E, Wannemuehler K, Naeem A, Umami RN, Nishimura Y, Shimizu H, Baba M, Adeniji A, Williams AJ, Kilpatrick DR, Oberste MS, Wassilak SG, Tomori O, Pallansch MA, Kew O. 2013. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 87:4907-4922. http://dx.doi.org/10.1128/JVI.02954-12.
11. World Health Organization. 1997. Manual for the virological investigation of poliomyelitis. WHO/EPI/GEN/97.1. World Health Organization, Geneva, Switzerland.
12. World Health Organization. 2004. Manual for the virological investigation of poliomyelitis. WHO/IVB/04.10. World Health Organization, Geneva, Switzerland.
13. van der Avoort HG, Hull BP, Hovi T, Pallansch MA, Kew OM, Crainic R, Wood DJ, Mulders MN, van Loon AM. 1995. A comparative study of five methods of intratypic differentiation of polioviruses. J Clin Microbiol 33:2562-2566.
14. Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J, Campagnoli R, Mandelbaum M, De L, Yang SJ, Nix A, Kew OM. 2009. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol 47:1939-1941. http://dx.doi.org/10.1128/JCM.00702-09.
15. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30: 2725-2729. http://dx.doi.org/10.1093/molbev/mst197.
16. Altschul S, Gish W, Miller W, Myers E, Lipman D. 1990. Basic local alignment search tool. J Mol Biol 215:403-410. http://dx.doi.org/10.1016/S0022-2836(05)80360-2.
17. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. 1999. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265:178-184. http://dx.doi.org/10.1006/viro.1999.0003.
18. Martín J, Dunn G, Hull R, Patel V, Minor PD. 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 74:3001-3010. http://dx.doi.org/10.1128/JVI.74.7.3001-3010.2000.
19. Jorba J, Campagnoli R, De L, Kew O. 2008. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 82:4429-4440. http://dx.doi.org/10.1128/JVI.02354-07.
20. Rakoto-Andrianarivelo M, Guillot S, Iber J, Balanant J, Blondel B, Riquet F, Martin J, Kew O, Randriamanalina B, Razafinimpiasa L, Rousset D, Delpeyroux F. 2007. Co-circulation and evolution of polioviruses and species Centeroviruses in a district of Madagascar. PLoS Pathog 3:e191. http://dx.doi.org/10.1371/journal.ppat.0030191.
21. Avellón A, Cabrerizo M, de Miguel T, Pérez-Breña P, Tenorio A, Pérez JL, de Aragón MV, Trallero G. 2008. Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain. Emerg Infect Dis 14: 1807-1809. http://dx.doi.org/10.3201/eid1411.080517.
22. Zhang Y, Yan D, Zhu S, Wen N, Li L, Wang H, Liu J, Ye X, Ding Z, Wang D, Zhu H, Chen L, Hou X, An H, Liang X, Luo H, Kew O, Xu W. 2010. Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in China: current immunization strategy effectively prevented its sustained transmission. J Infect Dis 202:1780-1788. http://dx.doi.org/10.1086/657410.
23. Sharif S, Abbasi BH, Khurshid A, Alam MM, Shaukat S, Angez M, Rana MS, Zaidi SS. 2014. Evolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali District of southern Afghanistan during June 2009-February 2011.PLoS One 9:e88442. http://dx.doi.org/10.1371/journal.pone.0088442.
24. Famulare M, Chang S, Iber J, Zhao K, Adeniji JA, Bukbuk D, Baba M, Behrend M, Burns CC, Oberste MS. 2016. Sabin vaccine reversion in the field: a comprehensive analysis of Sabin-like poliovirus isolates in Nigeria. J Virol 90:317-331. http://dx.doi.org/10.1128/JVI.01532-15.
25. Adu F, Iber J, Bukbuk D, Gumede N, Yang SJ, Jorba J, Campagnoli R, Sule WF, Yang CF, Burns C, Pallansch M, Harry T, Kew O. 2007. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res 127:17-25. http://dx.doi.org/10.1016/j.virusres.2007.03.009.
26. Yan D, Zhang Y, Zhu S, Chen N, Li X, Wang D, Ma X, Zhu H, Tong W, Xu W. 2014. Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China. Clin Vaccine Immunol 21: 1012-1018. http://dx.doi.org/10.1128/CVI.00196-14.
27. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman EV, Kew OM, Agol VI. 2003. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol 77:12460-12465. http://dx.doi.org/10.1128/JVI.77.23.12460-12465.2003.
28. Savolainen-Kopra C, Samoilovich E, Kahelin H, Hiekka AK, Hovi T, Roivainen M. 2009. Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages. J Gen Virol 90:1859-1868. http://dx.doi.org/10.1099/vir.0.010942-0.
29. Tao Z, Zhang Y, Liu Y, Xu A, Lin X, Yoshida H, Xiong P, Zhu S, Wang S, Yan D, Song L, Wang H, Cui N, Xu W. 2013. Isolation and characterization of a type 2 vaccine-derived poliovirus from environmental surveillance in China, 2012. PLoS One 8:e83975. http://dx.doi.org/10.1371/journal.pone.0083975.
30. Razafindratsimandresy R, Joffret ML, Rabemanantsoa S, Andriamamonjy S, Heraud JM, Delpeyroux F. 2013. Reemergence of recombinant vaccine-derived polioviruses in healthy children, Madagascar. Emerg Infect Dis 19:1008-1010. http://dx.doi.org/10.3201/eid1906.130080.
31. Sharma DK, Nalavade UP, Varose SY, Deshpande JM. 2015. Vaccinederived polioviruses not detected by global surveillance screening assay. Emerg Infect Dis 21:1880-1881. http://dx.doi.org/10.3201/eid2110.150702.
32. Yakovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP, Eremeeva TP, Baykova OY, Chumakov KM, Agol VI. 2006. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J Virol 80: 2641-2653. http://dx.doi.org/10.1128/JVI.80.6.2641-2653.2006.
33. Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, Eremeeva TP, Krasnoproshina LI, Romanenkova NI, Rozaeva NR, Sirota L, Agol VI, Chumakov KM. 2005. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 79:1062-1070. http://dx.doi.org/10.1128/JVI.79.2.1062-1070.2005.
34. van der Sanden S, Pallansch MA, van de Kassteele J, El-Sayed N, Sutter RW, Koopmans M, van der Avoort H. 2009. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol 83:8693-8704. http://dx.doi.org/10.1128/JVI.02388-08.
35. Matsuura K, Ishikura M, Yoshida H, Nakayama T, Hasegawa S, Ando S, Horie H, Miyamura T, KitamuraT. 2000. Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in Toyama Prefecture. Appl Environ Microbiol 66: 5087-5091. http://dx.doi.org/10.1128/AEM.66.11.5087-5091.2000.
36. Esteves-Jaramillo A, Estivariz CF, Penaranda S, Richardson VL, Reyna J, Coronel DL, Carrion V, Landaverde JM, Wassilak SG, Perez-Sanchez EE, Lopez-Martinez I, Burns CC, Pallansch MA. 2014. Detection of vaccine-derived polioviruses in Mexico using environmental surveillance. J Infect Dis 210:S315-S323. http://dx.doi.org/10.1093/infdis/jiu183.
37. Buttinelli G, Donati V, Fiore S, Marturano J, Plebani A, Balestri P, Soresina AR, Vivarelli R, Delpeyroux F, Martin J, Fiore L. 2003. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 84:1215-1221. http://dx.doi.org/10.1099/vir.0.18974-0.
38. Blomqvist S, Bruu AL, Stenvik M, Hovi T. 2003. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J Gen Virol 84:573-580. http://dx.doi.org/10.1099/vir.0.18708-0.
39. Zhang Y, Zhu S, Yan D, Liu G, Bai R, Wang D, Chen L, Zhu H, An H, Kew O, Xu W. 2010. Natural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region. PLoS One 5:e15300. http://dx.doi.org/10.1371/journal.pone.0015300.
40. Dedepsidis E, Pliaka V, Kyriakopoulou Z, Brakoulias C, Levidiotou-Stefanou S, Pratti A, Mamuris Z, Markoulatos P. 2008. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant. FEMS Immunol Med Microbiol 52:343-351. http://dx.doi.org/10.1111/j.1574-695X.2008.00381.x.
41. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD. 1993. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26. http://dx.doi.org/10.1006/viro.1993.1003.
42. Muzychenko AR, Lipskaya GY, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI. 1991. Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res 21:111-122. http://dx.doi.org/10.1016/0168-1702(91)90002-D.
43. Svitkin YV, Alpatova GA, Lipskaya GY, Maslova SV, Agol VI, Kew O, Meerovitch K, Sonenberg N. 1993. Towards development of an in vitro translation test for poliovirus neurovirulence. Dev Biol Stand 78:27-32.
44. Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, DeMartino J, Rozhon E, Schwartz J, Girijavallabhan V, O'Connell J, Arnold E. 1997. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5:961-978. http://dx.doi.org/10.1016/S0969-2126(97)00249-9.
45. Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, Halmut T, Silberstein I, Alfandari J, Quay J, Fisher T, Robinov J, Kew OM, Crainic R, Mendelson E. 2000. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 38:3729-3734.
46. Pilipenko EV, Blinov VM, Romanova LI, Sinyakov AN, Maslova SV, Agol VI. 1989. Conserved structural domains in the 5'-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence. Virology 168:201-209. http://dx.doi.org/10.1016/0042-6822(89)90259-6.
47. Han JQ, Townsend HL, Jha BK, Paranjape JM, Silverman RH, Barton DJ. 2007. A phylogenetically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNase L. J Virol 81:5561-5572. http://dx.doi.org/10.1128/JVI.01857-06.
48. Pilipenko EV, Poperechny KV, Maslova SV, Melchers WJ, Slot HJ, Agol VI. 1996. Cis-element, oriR, involved in the initiation of (+) strand poliovirus RNA: a quasi-globular multi-domain RNA structure maintained by tertiary ('kissing') interactions. EMBO J 15:5428-5436.
49. Georgescu MM, Delpeyroux F, Tardy-Panit M, Balanant J, Combiescu M, Combiescu AA, Guillot S, Crainic R. 1994. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 68:8089-8101.
50. Nathanson N, Kew OM. 2010. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. Am J Epidemiol 172:1213-1229. http://dx.doi.org/10.1093/aje/kwq320.
51. Anis E, Kopel E, Singer SR, Kaliner E, Moerman L, Moran-Gilad J, Sofer D, Manor Y, Shulman LM, Mendelson E, Gdalevich M, Lev B, Gamzu R, Grotto I. 2013. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill 18:20586. http://dx.doi.org/10.2807/1560-7917.ES2013.18.38.20586.
52. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW, Cochi SL. 1995. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine-a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 332:500-506. http://dx.doi.org/10.1056/NEJM199502233320804.
53. Izurieta HS, Sutter RW, Baughman AL, Strebel PM, Stevenson JM, Wharton M. 1995. Vaccine-associated paralytic poliomyelitis in the United States: no evidence of elevated risk after simultaneous intramuscular injections of vaccine. Pediatr Infect Dis J 14:840-846. http://dx.doi.org/10.1097/00006454-199510000-00004.
54. Ma S, Du Z, Feng M, Che Y, Li Q. 2015. A severe case of co-infection with enterovirus 71 and vaccine-derived poliovirus type II. J Clin Virol 72:25-29. http://dx.doi.org/10.1016/j.jcv.2015.08.017.
55. World Health Organization. 2013. Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2013-2018). WHO/POLIO/13.02. World Health Organization, Geneva, Switzerland. http://www.polioeradication.org/Default.aspx?tabid=116&Tag=strategy.
56. World Health Organization. 2015. Global Polio Eradication Initiative. World Health Assembly resolution WHA68.3. http://www.polioeradication.org/Default.aspx?tabid=123&Tag=resolution.